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Introduction {#sec006}
============

Scoliosis, which is defined as a lateral curvature of the spine, is the most common deformity of the spine and has been focused for centuries by physicians\[[@pone.0137886.ref001]\]. Multi-segmental spinal instrumentation and fusion, and sometimes osteotomy were effective methods of correcting scoliosis, but were commonly associated with massive blood loss requiring blood transfusion\[[@pone.0137886.ref002]--[@pone.0137886.ref007]\]. Either allogenic or autologous blood transfusions can increase the length of hospital stay and medical cost. Allogenic blood transfusion in particular increased the rate of infectious disease, hemolytic reaction, septicemia, acute lung injury, severe immunoreaction, coagulation disorders, renal injury or failure, and even death\[[@pone.0137886.ref008]--[@pone.0137886.ref012]\].

Since the 1990s, antifibrinolytic agents, such as aprotinin, tranexamic acid (TXA) and epsilon aminocaproic acid (EACA), have been suggested to use in complex surgery to reduce bleeding. Aprotinin has a role of antiplasmin by inhibiting serine protease while TXA and EACA bind with the receptor competing to lysine to suppress fibrinolysis. More and more evidence revealed that these antifibrinolytic agents were successful to reduce perioperative blood loss and blood transfusion requirements in major pediatric surgery, cardiac surgery, total hip replacement arthroplasty and total knee replacement arthroplasty\[[@pone.0137886.ref013]--[@pone.0137886.ref015]\]. However, the efficacy and safety of these agents in scoliosis surgery remains yet to be determined.

The objective of this systematic review and meta-analysis was to determine whether the antifibrinolytic agents including aprotinin, TXA and EACA could effectively and safely reduce perioperative blood loss and transfusion requirements in scoliosis surgery. We followed the PRISMA guidelines to help improve reporting quality of our study (see [S1 PRISMA Checklist](#pone.0137886.s001){ref-type="supplementary-material"}).

Materials and Methods {#sec007}
=====================

Data Sources and Search Strategy {#sec008}
--------------------------------

Interrelated randomized controlled trials (RCTs) and retrospective studies were distinguished in the MEDLINE and EMBASE databases and the Cochrane Database of Systematic Reviews and Controlled Trials from January 1980 through July 2014. Key words used in the search included antifibrinolytic agents, tranexamic acid, epsilon aminocaproic acid, aprotinin, spinal curvatures, scoliosis, kyphosis, lordosis, posterior lumbar spine fusion, randomized controlled trial, and comparative study. Once studies met the eligible criteria, they would be included even published in gray literature. The search was carried out without any linguistic restriction. Two investigators independently reviewed the title, abstract, and the full text of all articles. Eligible trials were chosen according to the inclusion criteria.

Study Eligibility Criteria and Exclusion Criteria {#sec009}
-------------------------------------------------

Articles were selected on the basis of the following criteria: subjects were diagnosed with scoliosis and received correction surgery. Articles were excluded if the patients had one of the following conditions: (1) severe cardiopulmonary disease, hepatic or renal dysfunction; (2) extension of prothrombin time (PT) and activated partial thromboplastin time (APTT), decrease of platelet counts; (3) medical history of coagulation disorders; (4) intake of any anticoagulant drug within a week before surgery.

Assessment of Risk of Bias {#sec010}
--------------------------

According to the Cochrane guidelines\[[@pone.0137886.ref016]\], two independent researchers and a managing reviewer assessed the included studies for risk of bias. Cochrane bias scale is composed of 7 parts: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome data, incomplete outcome data, selective reporting and other bias. Based on the report and appropriateness of methods, the included studies were graded accordingly: (1) low risk (methods were indicated and proper); (2) high risk (methods were indicated but improper); or (3) moderate risk (methods were not indicated).

Data Collection {#sec011}
---------------

Two reviewers specialized in scoliosis extracted relevant data independently. If there was any disagreement, it would be decided by the senior professional reviewer. The data extracted was mainly divided into two parts, study characteristics and measuring outcomes. Study characteristics included the following items: the name of first author, year of publication, sample size, intervention, dose, number of levels fused, transfusion trigger and surgical procedure. Total blood loss, intraoperative blood loss, postoperative blood loss, blood transfusion volume and transfusion rate were extracted as the measuring outcomes of effectiveness while adverse event (thromboembolism, cerebrovascular accident, seizure, myocardial infarction, renal dysfunction or failure and even death) were extracted as the measuring outcomes of safety.

Data Analysis {#sec012}
-------------

The data extracted was processed by Review Manager 5.0 software with a random-effect model. The odds ratio (OR) and 95% confidence interval (CI) were as statistical data to process dichotomous variables. If measuring outcome in the studies maintained uniformly standard, mean difference and 95% CI were as statistical data to process continuous variables. Otherwise, the standardized mean difference and 95% CI were calculated. The size of heterogeneity was calculated by the χ^2^ statistic, including *P* value and I^2^. If *P* \> .10 and I^2^ ≤ 50%, the fixed-effect model would be applied on the meta-analysis. The random-effect model was used if *P* ≤ .10, I^2^ \> 50%. The included studies were also subgrouped according to the specific pharmacologic interventions (aprotinin, or TXA, or EACA).

Results {#sec013}
=======

Description of Study {#sec014}
--------------------

The search identified 59 articles ([Fig 1](#pone.0137886.g001){ref-type="fig"}), of which 27 were excluded. Excluded studies included case reports, reviews, critical articles, and articles that did not match the inclusion criteria. Of the remaining 32 articles, 12 were RCTs and 20 were retrospective studies. After a full text reading, 3 randomized controlled trials and 11 retrospective studies were further excluded because of incompatible protocol specifications, use of outcome measures that were not specified in the meta-analysis, inclusion of patients without scoliosis, no use of antifibrinolytic agents, or comparisons involving different doses of antifibrinolytic agent.

![Flow diagram for study selection process in this meta-analysis.](pone.0137886.g001){#pone.0137886.g001}

In total, 18 studies with 1,158 patients fitted the criteria and were included in the meta-analysis. Among them, there were 9 RCTs\[[@pone.0137886.ref017]--[@pone.0137886.ref025]\], 7 retrospective case-control studies\[[@pone.0137886.ref026]--[@pone.0137886.ref032]\], and 2 retrospective cohort studies\[[@pone.0137886.ref033],[@pone.0137886.ref034]\]. One\[[@pone.0137886.ref017]\] of the 9 remaining RCTs lacked required data (standard deviation of blood loss and blood transfusion volume), thus 8 RCTs with 450 patients were included for evaluation of pharmacologic efficacy. All the 18 studies were included for evaluation of pharmacologic safety. Among these 18 studies, five reported the use of TXA, 4 reported EACA, 6 reported aprotinin, 1 reported both TXA and EACA, and 2 reported both TXA and aprotinin ([Table 1](#pone.0137886.t001){ref-type="table"}).

10.1371/journal.pone.0137886.t001

###### Characteristics of the Studies Included.

![](pone.0137886.t001){#pone.0137886.t001g}

  Author                                        Year   Age(E/C)                     Intervention   Size (E/C)      Dose(loading/ continuous infusion)                  Number of levels fused (E/C)   Transfusion trigger                          Type        Procedure     Design
  --------------------------------------------- ------ ---------------------------- -------------- --------------- --------------------------------------------------- ------------------------------ -------------------------------------------- ----------- ------------- --------
  Khoshhal                                      2003   14.5/14.1                    aprotinin      43(15/28)       4mg/kg+1mg/kg/hr                                    10/10                          Hgb \< 7g/dL or Hct \< 20%                   IS          SF            RCT
  Karapurkar                                    2002   12--25                       aprotinin      49(24/25)       2\*10\^4 IU/kg+5\*10\^3 IU/kg/4hr                   /                              BEBL \< 90% or Hct \< 30% or Hgb \< 10g/dl   KS          SF            RCT
  Lentschener                                   1999   46±9/51±11                   aprotinin      72(35/37)       2\*10\^6 KIU/kg+5\*10\^5 KIU/kg/hr                  /                              Hct \< 26%                                   AD          SF            RCT
  Cole                                          2003   13±4.7/12.2±3.8              aprotinin      44(21/23)       240mg/m2+56mg/m2/hr                                 14.5/12.2                      Hgb \< 8.5 g/dl or Hct \< 27%                NS          SF            RCT
  Tayyab                                        2008   47±15/41±15                  aprotinin      82(41/41)       2\*10\^6KIU+5\*10\^5 KIU/hr                         11.2/10.7                      Hgb \< 7g/dL                                 PS and SS   SF            nRCT
  Kasimian                                      2008   12.4/14.8                    aprotinin      31(14/17)       2\*10\^5KIU/kg+5\*10\^4 KIU/kg/hr                   14.4/15.3                      Hct≤24%                                      NS          SF            nRCT
  Xu                                            2012   19.1±3.2/20.4±3.1            TXA            40(20/20)       20mg/kg+10mg/kg/hr                                  12.7/13.1                      Hgb \< 8g/dL                                 AIS         SF            RCT
  Sethna                                        2005   13.6±1.8/14.0±2.0            TXA            44(23/21)       100mg/kg+10mg/kg/hr                                 14/13                          Hct \< 25%                                   PS and SS   SF            RCT
  Neilipovitz                                   2001   14.1±2.1/13.7±2.5            TXA            40(22/18)       10mg/kg+1mg/kg/hr                                   15 /14                         Hgb \< 7g/dL                                 PS and SS   SF            RCT
  Yagi                                          2012   15.2±2.9/15.5±3.0            TXA            106(43/63)      1g+100mg/hr                                         12.2/12.1                      Hgb \< 7g/dL                                 AIS         SF            nRCT
  Lykissas                                      2013   14.7(12--19)/13.5(11--16)    TXA            49(25/24)       100mg+10mg/hr                                       10.7/12.6                      Hgb \< 7g/dL                                 AIS         SF            nRCT
  Pineda                                        2004   13.5±1.6/14.5±1.3            EACA           36(19/17)       100mg/kg+10mg/kg/hr                                 12/12.1                        Hgb \< 7g/dL                                 IS          SF            RCT
  Thompson                                      2008   14.0±2.4/12.3±2.8            EACA           96(62/34)       100mg/kg+10mg/kg/hr                                 15/14                          Hgb \< 7g/dL                                 NS          SF            nRCT
  Pineda                                        2001   14.5±1.6/13.3±1.3            EACA           59(28/31)       100mg/kg+10mg/kg/hr                                 12/12                          Hgb \< 7g/dL                                 IS          SF            nRCT
  Lorio                                         2013   N/A                          EACA           33(17/16)       100mg/kg+10mg/kg/hr                                 /                              Hgb \< 7g/dL                                 AIS         SF with PO    nRCT
  Verma                                         2014   15.3±2.4,14.6±1.9/15.0±2.4   TXAEACA        125(36,42/47)   TXA:10mg/kg +1mg/kg/hrEACA:100mg/kg +10mg/kg/hr     8.8,9.5/9.0                    I: Hct \< 25% P: Hct \< 22%                  AIS         SA            RCT
  Newton                                        2012   13.7                         aprotininTXA   136(30,42/64)   /                                                   /                              /                                            PS and SS   SF with VCR   nRCT
  Khurana[★](#t001fn002){ref-type="table-fn"}   2012   26.3                         aprotininTXA   73(28,26/17)    Aprotinin:1\*10\^6 KIU +5\*10\^5 KIU/hrTXA:2g+N/A   12.3,11.9/7.1                  /                                            AD          SF            nRCT

E/C, experimental group/control group; TXA, tranexamic acid; EACA, epsilon aminocaproic acid; I, intraoperative; P, postoperative; Hct, hematocrit; PS, primary scoliosis; SS, secondary scoliosis; AD, adult deformity; NS, neuromuscular scoliosis; AIS, adolescent idiopathic scoliosis; IS, idiopathic scoliosis; KS, Kypho scoliosis; SF, spinal fusion; VCR, vertebral column resection; PO, Ponte osteotomy; BEBL, baseline estimated blood volume; RCT, randomized control trial; nRCT, non-randomized control trial.

★the operative approach in this study was either anterior, or posterior, or combined. In the others, all posterior

Risk of Bias {#sec015}
------------

The methodological quality of the included studies was assessed independently by two reviewers using Review Manager Software. The outcome was summarized in [Table 2](#pone.0137886.t002){ref-type="table"}. Blood transfusion rates were used to generate a funnel plot analysis of publication bias ([Fig 2](#pone.0137886.g002){ref-type="fig"}). The asymmetric nature of the resultant plot indicated the presence of publication bias.

![Funnel plot to assess publication bias.](pone.0137886.g002){#pone.0137886.g002}

10.1371/journal.pone.0137886.t002

###### Assessment of Risk of Bias in the Studies Included.

![](pone.0137886.t002){#pone.0137886.t002g}

                         Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome data   Incomplete outcome data   Selective reporting   Other bias
  ---------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------- ------------------------- --------------------- ------------
  RCT                                                                                                                                                                                              
      Lentschener 1999   L                            L                        L                                        L                          L                         L                     L
      Neilipovitz 2001   L                            M                        L                                        L                          L                         L                     L
      Karapurkar 2002    M                            M                        M                                        M                          L                         L                     L
      Cole 2003          L                            L                        L                                        L                          L                         L                     L
      Pineda 2004        M                            L                        L                                        L                          L                         L                     L
      Sethna 2005        L                            L                        L                                        L                          L                         L                     L
      Xu 2012            M                            M                        M                                        M                          L                         L                     M
      Verma 2014         L                            L                        L                                        L                          L                         L                     L
      Khoshhal 2003      M                            M                        M                                        M                          L                         L                     L
  nRCT                                                                                                                                                                                             
      Tayyab 2008        H                            H                        H                                        M                          M                         L                     M
      Newton 2012        H                            H                        H                                        M                          M                         L                     M
      Khurana 2012       H                            H                        H                                        M                          M                         L                     L
      Kasimian 2008      H                            H                        H                                        M                          M                         L                     M
      Yagi 2012          H                            H                        H                                        M                          M                         L                     M
      Thompson 2008      H                            H                        H                                        H                          M                         L                     M
      Lykissas 2013      H                            H                        H                                        H                          M                         L                     M
      Pineda 2001        H                            H                        H                                        M                          M                         L                     M
      Lorio 2013         H                            H                        H                                        M                          M                         L                     M

L: low risk (methods were indicated and proper); H: high risk (methods were indicated but improper); M: moderate risk (methods were not indicated); RCT: randomized control trial; nRCT: non-randomized control trial.

Baseline Characteristics {#sec016}
------------------------

The essential characteristics of the patients with antifibrinolytic agent (experimental group) were brought into correspondence with those with placebo (control group) in every included study. There were no significant differences in the baseline values of preoperative Cobb angle, scoliosis etiology classification, preoperative hemoglobin level, number of levels fused, surgical duration, and estimated blood volume or lifestyle factors between the two groups. The consistency of preoperative factors ensured to wipe off potential bias.

Perioperative Blood Loss and Blood Transfusion Volume {#sec017}
-----------------------------------------------------

High-quality evidence was available from 8 RCT studies (450 patients) in which antifibrinolytic agents were more effective than placebo in reducing total blood loss (weighted mean difference \[WMD\] = −601.40, 95% CI \[−896.16, −306.64\]; P \< 0.0001; [Fig 3](#pone.0137886.g003){ref-type="fig"}). There was high-quality evidence from 6 studies (253 patients) in which antifibrinolytic agents were more effective than placebo in reducing perioperative blood transfusion volume (WMD = −474.98, 95% CI \[−754.67, 195.30\]; P = 0.0009; [Fig 4](#pone.0137886.g004){ref-type="fig"}). There was high-quality evidence from 8 studies (450 patients) in which antifibrinolytic agents were more effective than placebo in reducing intraoperative blood loss (WMD = −409.25, 95% CI \[−621.94, −196.57\], P = 0.0002, [Fig 5](#pone.0137886.g005){ref-type="fig"}). There was high-quality evidence from 8 studies (450 patients) in which antifibrinolytic agents were more effective than placebo in reducing postoperative blood loss (WMD = −250.30, 95% CI \[−465.30, −35.31), P = 0.02, [Fig 6](#pone.0137886.g006){ref-type="fig"}).

![Forest plot diagram showing the effect of antifibrinolytic agents on total blood loss.](pone.0137886.g003){#pone.0137886.g003}

![Forest plot diagram showing the effect of antifibrinolytic agents on blood transfusion requirements.](pone.0137886.g004){#pone.0137886.g004}

![Forest plot diagram showing the effect of antifibrinolytic agents on intra-operative blood loss.](pone.0137886.g005){#pone.0137886.g005}

![Forest plot diagram showing the effect of antifibrinolytic agents on post-operative blood loss.](pone.0137886.g006){#pone.0137886.g006}

Perioperative Blood Transfusion Rate {#sec018}
------------------------------------

The transfusion rate was 44.6% (108/242) in the patients with antifibrinolytic agents and 68.3% (142/208) in the patients with placebo. There was high-quality evidence from 8 studies (450 patients) in which antifibrinolytic agents were more effective than placebo in reducing perioperative blood transfusion rate (OR = 0.38, 95% CI \[0.25, 0.58\], P \< 0.00001, [Fig 7](#pone.0137886.g007){ref-type="fig"}).

![Forest plot diagram showing the effect of antifibrinolytic agents on blood transfusion rate.](pone.0137886.g007){#pone.0137886.g007}

Adverse Event {#sec019}
-------------

Only 8 adverse events were reported in all the included studies. One pulmonary embolism and 3 deep vein thrombosis happened in the patients with antifibrinolytic agents while other 4 deep vein thrombosis occurred in the patients with placebo. There was moderate-quality evidence from the 18 studies (1,158 patients) in which no significant difference was found between antifibrinolytic agents and placebo in the rate of adverse events (OR = 0.84, 95% CI \[0.25, 2.88\], P = 0.78; [Fig 8](#pone.0137886.g008){ref-type="fig"}).

![Forest plot diagram showing the effect of antifibrinolytic agents on adverse events rate.](pone.0137886.g008){#pone.0137886.g008}

Subgroup Analysis {#sec020}
-----------------

The studies were divided into three subgroups according to the use of specific antifibrinolytic agent ([Table 3](#pone.0137886.t003){ref-type="table"}). TXA, EACA and aprotinin were all more effective than placebo in reducing perioperative blood loss and blood transfusion requirements. Both TXA and aprotinin were more effective than placebo in reducing intraoperative blood loss and blood transfusion rate. No significant difference existed between EACA and placebo, or between aprotinin and placebo in reducing postoperative blood loss. One pulmonary embolism occurred in TXA group and 3 deep vein thromboses in aprotinin group. No significant difference existed between TXA and placebo, or between aprotinin and placebo in the adverse event rate. No adverse event was reported in the EACA group.

10.1371/journal.pone.0137886.t003

###### Different Antifibrinolytic Agents Subgroup Analysis.

![](pone.0137886.t003){#pone.0137886.t003g}

  Outcome and subgroup                           Studies   Participants   Statistical method                     Effect estimate                p          X^2^    I^2^
  ---------------------------------------------- --------- -------------- -------------------------------------- ------------------------------ ---------- ------- ------
  Intraoperative blood loss                                                                                                                                        
      TXA                                        4         207            Mean difference (IV, random, 95% CI)   −605.12, (−974.02, −236.22)    0.001      8.49    65%
      Amicar                                     2         125            Mean difference (IV, random, 95% CI)   −162.83, (−405.94, 80.27)      0.19       1.95    49%
      Aprotinin                                  3         165            Mean difference (IV, random, 95% CI)   −318.39, (−475.80, −160.98)    \<.0001    0.84    0%
  Postoperative blood loss                                                                                                                                         
      TXA                                        2         123            Mean difference (IV, random, 95% CI)   −360.97, (−531.18, −190.77)    \<.0001    2.14    53%
      Amicar                                     2         125            Mean difference (IV, random, 95% CI)   −150.99, (−393.38, 91.41)      0.22       3.55    72%
      Aprotinin                                  2         121            Mean difference (IV, random, 95% CI)   −224.47, (−693.46, 244.52)     0.35       11.63   91%
  Total blood loss                                                                                                                                                 
      TXA                                        4         207            Mean difference (IV, random, 95% CI)   −828.60, (−1285.48, −371.72)   0.0004     9.96    70%
      Amicar                                     2         125            Mean difference (IV, random, 95% CI)   −329.34, (−552.89, −105.78)    0.004      0       0%
      Aprotinin                                  3         165            Mean difference (IV, random, 95% CI)   −482.47, (−821.28, −143.66)    0.005      6.4     69%
  Perioperative Blood Transfusion Requirements                                                                                                                     
      TXA                                        3         124            Mean difference (IV, random, 95% CI)   −587.00, (−1073.03, −100.96)   0.02       14.26   86%
      Amicar                                     1         36             Mean difference (IV, random, 95% CI)   −280.00, (−549.75, −10.25)     0.04       N/A     N/A
      Aprotinin                                  2         93             Mean difference (IV, random, 95% CI)   −389.14, (−586.09, −192.19)    0.0001     0.15    0%
  Transfusion rate                                                                                                                                                 
      TXA                                        4         207            Odds ratio (M-H, fixed, 95% CI)        0.53, (0.29, 0.95)             0.03       0.9     0%
      Amicar                                     2         125            Odds ratio (M-H, fixed, 95% CI)        0.62, (0.29, 1.32)             0.21       0.01    0%
      Aprotinin                                  3         165            Odds ratio (M-H, fixed, 95% CI)        0.17, (0.08, 0.37)             \<.00001   0.59    0%
  Adverse Event                                                                                                                                                    
      TXA                                        8         513            Odds ratio (M-H, fixed, 95% CI)        1.54, (0.09, 25.26)            0.76       N/A     N/A
      Amicar                                     5         313            Odds ratio (M-H, fixed, 95% CI)        Not estimable                                     
      Aprotinin                                  8         469            Odds ratio (M-H, fixed, 95% CI)        0.96, (0.28, 3.29)             0.95       3.26    8%

Discussion {#sec021}
==========

Effective control of perioperative blood loss helps increase the patient's tolerance to surgery, decrease postoperative infection rate, reduce the probability of blood transfusion, shorten hospital stays and decrease medical cost. This meta-analysis indicated that the antifibrinolytic agents aprotinin, TXA and EACA could reduce perioperative blood loss and blood transfusion volume effectively in scoliosis surgery. There was no evidence that use of these agents was a risk factor to increase the incidence of adverse events. TXA and aprotinin appeared more effective than EACA according to the results of this analysis.

Fibrinolysis is the liquefied process of fibrin formed in blood clotting. It consists of two elementary steps, activation of plasminogen and degradation of fibrin\[[@pone.0137886.ref035]--[@pone.0137886.ref037]\]. Aprotinin was first extracted from bovine tissues and is now also produced by recombinant technology as a serine proteinase inhibitor\[[@pone.0137886.ref038],[@pone.0137886.ref039]\]. The drug was a pioneering antifibrinolytic agent used in surgery. It was first used in the 1960s to reduce blood loss in major cardiac surgery involving cardiopulmonary bypass\[[@pone.0137886.ref017]\]. In 1993, aprotinin was approved by the Food and Drug Administration (FDA) as a hemostatic and was widely used in coronary artery bypass graft procedures. However, in 2006, Mangano et al\[[@pone.0137886.ref040]\] performed an observational study involving 4,374 patients undergoing revascularization which investigated adverse events associated with aprotinin in cardiac surgery. This study indicated that the use of aprotinin might have a positive correlation with renal failure, myocardial infarction, cerebrovascular accident, and death\[[@pone.0137886.ref040],[@pone.0137886.ref041]\]. Just because of this, aprotinin was withdrawn by FDA in 2007 due to safety concerns. It was not likely approved for use again in the United States or Canada in cardiac surgery. More recently, lysine analogs (TXA and EACA) have replaced aprotinin in reducing perioperative blood loss and blood transfusion requirements due to the improved safety profile of these agents. Both EACA and TXA inhibited plasminogen from binding to the surface of fibrin\[[@pone.0137886.ref042]--[@pone.0137886.ref045]\].

Few RCTs or observational studies have been reported directly comparing TXA, EACA, and aprotinin in terms of benefit in reducing perioperative blood loss and transfusion requirements. Makhija et al\[[@pone.0137886.ref044]\] and Verma et al\[[@pone.0137886.ref024]\] concluded that no significant difference was found between TXA and EACA in efficacy based on their studies of thoracic aortic surgery and scoliosis surgery, respectively. Compared with lysine analogs, aprotinin was more efficient in reducing perioperative blood loss \[[@pone.0137886.ref045]\], although there was controversy over whether it would also be able to decrease perioperative blood transfusion requirements more efficiently\[[@pone.0137886.ref045]--[@pone.0137886.ref047]\]. Our results were not completely consistent with these findings. This meta-analysis demonstrated that TXA and aprotinin were more effective in reducing perioperative blood loss and transfusion requirements in scoliosis surgery compared with EACA. However, this conclusion needs to be further confirmed because of the lack of well-designed RCTs directly comparing these agents.

The medical community has expressed doubts over the safety of antifibrinolytic agents over the past few years. Some large meta-analyses have shown that use of antifibrinolytic agents might increase the risk of death, MI, cerebrovascular accidents, seizure, and renal injury or failure\[[@pone.0137886.ref048]--[@pone.0137886.ref051]\]. In this analysis, a total of 18 papers including 1,158 patients were eligible for inclusion for evaluation of safety. Surprisingly, none of the included paper reported the above-mentioned adverse events in any patient. One possible reason might be the underlying disease that was operated. Stroke, MI, renal injury or failure and even death were the common complications of cardiac surgery so the rates of these adverse events would be high no matter whether antifibrinolytic agents were used or not. The other one might be due to our exclusion criteria in data collection that we excluded the patients who originally had severe cardiopulmonary disease, hepatic or renal dysfunction.

Use of antifibrinolytic agents is a theoretical risk factor for thromboembolism after operation. However, only 8 thromboembolic events were reported in our meta-analysis. Four happened in the patients with antifibrinolytic agents and the other 4 occurred in those with placebo. In the patients with antifibrinolytic agents, 1 pulmonary embolism (PE) happened in a patient with TXA, 3 deep vein thromboses (DVT) occurred in those with aprotinin, while none in the patients with EACA. Unlike extremity operations with high complications of DVT or PE, the underlying disease of spine that was operated in our meta-analysis had a very low rate of thromboembolism no matter whether antifibrinolytic agents were used or not. The low incidence of thromboembolic complications in our meta-analysis was largely consistent with previous papers. Sansur et al\[[@pone.0137886.ref052]\] reported that the rate of PE was 0.2% (12 cases), and the rate of DVT was 0.18% (9 cases) in a total of 4,980 operated cases of idiopathic adult scoliosis. Similarly, Jain et al\[[@pone.0137886.ref053]\] found that the incidence of venous thromboembolism in 21,955 children with spinal fusions was 0.21% (0.096--0.385%), while the rate of PE was 0.02% (0--0.06%). Thus, we believed that use of antifibrinolytic agents was not a risk factor for adverse events, particularly thromboembolism, in scoliosis surgery.

This study had some limitations. According to our search results and inclusion criteria, 9 RCTs and 9 observational studies were included. The small quantity of RCTs and incomplete data might reduce the quality of evidence and the strength of analysis. There was no clear attempt at random sequence generation, allocation concealment, blinding of participants and personnel, or blinding of outcome data in 2 RCTs\[[@pone.0137886.ref020],[@pone.0137886.ref025]\] for efficacy evaluation. In addition, the age of the subjects in each study included was different; some studies were restricted to children, others involved adults. The pathogenesis of scoliosis in different studies varied; some were idiopathic and others were secondary in nature. Some studies proved that perioperative blood loss in secondary scoliosis surgery was much greater than that in idiopathic scoliosis surgery. In addition, there might be some performance bias due to surgical time, fusion levels, transfusion trigger, dose of antifibrinolytic agents and intraoperative MAP. Finally, there were 2 RCTs\[[@pone.0137886.ref024],[@pone.0137886.ref025]\] presented in diagrammatic form (represented by the error bars which were measures directly), from which we extracted primary data by ratio-metric conversion, another potential source of bias.

Conclusion {#sec022}
==========

Aprotinin, TXA, and EACA were all able to reduce perioperative blood loss and transfusion requirements in scoliosis surgery. There was no evidence that use of antifibrinolytic agents was a risk factor for adverse events, especially thromboembolism, in scoliosis surgery. Nevertheless, the number of either total patients or adverse events was relatively small. Further multicenter, large-sample, double-blind RCTs are required to confirm the efficacy and safety of the three antifibrinolytic agents in spine surgery.
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